Jeremić B, Sibamoto J, Abe M
Department of Oncology, Clinical-Hospital Centre, Kragujevac, Yugoslavia.
Srp Arh Celok Lek. 1996 Jul-Aug;124(7-8):169-74.
The in vitro chemosensitivity testing aims at predicting the response of an individual tumour to chemotherapy choosing optimal agents for a particular patient. Among many chemosensitivity tests developed over the years [1-6], special emphasis was made on clonogenic assays that showed good use and correlation between laboratory and clinical data [7-9]. One of the assays used to predict the response to various anti-cancer modalities is the micronucleus assay using the cytokinesis-block [12-14]. This block is achieved by administration of Cytochalasin-B in order to prevent cytoplasmic, but not the nuclear, division. This leads to micronucleus formation which are counted in binuclear cells. Since there are only a few reports of the use of this assay in predicting chemosensitivity [13, 16], we explored the possibility of using this assay to predict chemosensitivity to various anti-cancer agents.
Exponentially growing SCC VII cells were treated with various concentrations of 11 anti-cancer agents: Mitomycin C, Doxorubicin (ADR), Epirubicin (EPI), Cisplatin, Carboplatin (CBDCA), Etoposide (VP-16), Vincristine, 5-fluorouracil, Methotrexate, Nimustine, and Dacarbazine for 1 hour. After that, Cytochalasin-B was added and dishes were incubated. After various time intervals, cells were fixed in situ and dried. Electron microscope was used to count the number of micronuclei (MN) in binucleate cells as well as multinucleate cells (MNC) in the total cell population. Cell survival was also evaluated by using the colony formation assay [18].
Maximal % of binucleate cells (BNC) was usually reached at 24-30 hours of culture, except for cells treated with ADR and EPI, in which it was reached at 30-72 hours (Figures 1 and 2). All drugs induced formation of micronuclei and dose-response curves for micronucleus frequency were obtained using the data at peak % BNC times. For all drugs, micronucleus frequency increased with concentration (Figure 3), but at the highest concentration used (considered to be overly toxic-Figure 4), the micronucleus frequency was rather lower. This decrease in micronucleus frequency was largely attributed to the decrease in % BNC. When the data at the highest concentrations of all drugs were excluded, a correlation was found between micronucleus frequency and surviving fraction (r = 0.85; p < 0,001) (Figure 5).
Since micronucleus formation is a sign of chromosome damage that leads to cell death, we used this assay to evaluate chemosensitivity in 11 widely used anticancer agents. Although they can be classified according to mechanism of action as different class agents, they have in common the formation of micronuclei as a sign of cytotoxicity. Cell cycle arrest observed in some agents might be evaluated by assessing the delay in increase of BNC and MNC. The difference observed regarding cell cycle arrest suggested different mechanisms of its action. MN frequency was almost dose-dependent at lower concentrations, but at the highest concentrations, it obviously decreased, showing, therefore, some discrepancies with the data obtained when radiosensitivity was tested that way [14], probably due to extreme toxicity of agents. The optimal concentrations seem to be those providing a 20-80% surviving fraction. Another slight difference, when compared with similar radiosensitivity studies is a decrease with longer duration of culture observed in chemosensitivity testings. The reason for this difference is still unknown, but it emphasized the necessity for choosing the optimal duration of culture, probably that necessary for reaching maximal % BNC. This assay seems useful in predicting chemosensitivity of at least some tumour cells to various (appropriate) concentrations of various anti-cancer agents. However, new studies are warranted to further use of this assay, before testing it in clinical practice.
体外化学敏感性测试旨在预测个体肿瘤对化疗的反应,为特定患者选择最佳药物。在过去几年开发的众多化学敏感性测试中[1-6],特别强调了克隆形成试验,该试验在实验室数据和临床数据之间显示出良好的实用性和相关性[7-9]。用于预测对各种抗癌方式反应的试验之一是使用胞质分裂阻滞的微核试验[12-14]。通过施用细胞松弛素-B来实现这种阻滞,以防止细胞质而非细胞核分裂。这导致微核形成,在双核细胞中进行计数。由于仅有少数关于该试验用于预测化学敏感性的报道[13,16],我们探讨了使用该试验预测对各种抗癌药物化学敏感性的可能性。
将指数生长的SCC VII细胞用11种抗癌药物的不同浓度处理:丝裂霉素C、阿霉素(ADR)、表柔比星(EPI)、顺铂、卡铂(CBDCA)、依托泊苷(VP-16)、长春新碱、5-氟尿嘧啶、甲氨蝶呤、尼莫司汀和达卡巴嗪,处理1小时。之后,加入细胞松弛素-B并培养培养皿。在不同时间间隔后,原位固定细胞并干燥。使用电子显微镜计数双核细胞以及总细胞群体中的多核细胞(MNC)中的微核(MN)数量。还通过集落形成试验[18]评估细胞存活率。
除了用ADR和EPI处理的细胞在30-72小时达到外,双核细胞(BNC)的最大百分比通常在培养24-30小时达到(图1和图2)。所有药物均诱导微核形成,并使用BNC百分比峰值时的数据获得微核频率的剂量反应曲线。对于所有药物,微核频率随浓度增加(图3),但在使用的最高浓度(认为毒性过大 - 图4)时,微核频率相当低。微核频率的这种降低很大程度上归因于BNC百分比的降低。当排除所有药物最高浓度的数据时,发现微核频率与存活分数之间存在相关性(r = 0.85;p < 0.001)(图5)。
由于微核形成是染色体损伤导致细胞死亡的标志,我们使用该试验评估11种广泛使用的抗癌药物的化学敏感性。尽管它们可根据作用机制分类为不同类别的药物,但它们的共同之处在于形成微核作为细胞毒性的标志。在某些药物中观察到的细胞周期停滞可通过评估BNC和MNC增加的延迟来评估。观察到的关于细胞周期停滞的差异表明其作用机制不同。在较低浓度下,MN频率几乎呈剂量依赖性,但在最高浓度下,它明显降低,因此与以这种方式测试放射敏感性时获得的数据存在一些差异[14],可能是由于药物的极端毒性。最佳浓度似乎是那些提供20-80%存活分数的浓度。与类似的放射敏感性研究相比另一个细微差异是在化学敏感性测试中观察到随着培养时间延长而降低。这种差异的原因仍然未知,但它强调了选择最佳培养时间的必要性,可能是达到最大BNC百分比所需的时间。该试验似乎可用于预测至少一些肿瘤细胞对各种(合适)浓度的各种抗癌药物的化学敏感性。然而,在临床实践中进行测试之前,需要进行新的研究以进一步使用该试验。